Neratinib Maleate

马来酸奈拉替尼

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameNeratinib Maleate
Drug Alias NameNeratinib奈拉替尼Neratinibum奈雷替尼马来酸来那替尼 +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitorsReceptor protein-tyrosine kinase erbB-4 inhibitors
TargetsReceptor protein-tyrosine kinase erbB-4Epidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBrain metastasesMetastatic breast cancerGastroesophageal Junction Neoplasms +[16] 
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaBreast Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2017/07/17
Country/TerritoryCzechiaBahamasBelgium +[57] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesConvalife (Shanghai) Co LtdZhejiang Fukang Pharmaceutical Co LtdBixink Therapeutics Co Ltd +[8] 
Inactive CompaniesDana-Farber Cancer InstituteJules Bordet InstituteWashington University School Of Medicine +[8] 
Active IndicationsBrain metastasesGastroesophageal Junction NeoplasmsSolid tumours +[9] 
Inactive IndicationsMetastatic breast cancerHepatic InsufficiencyProstatic Neoplasms, Castration-Resistant +[7] 

Other Information

ATC CodeL01EH02
Related LinksWikipediaDrugBankKEGG